Evidence map›Paper›PMID 41322414›Full record

ArticleFrontiers in immunology2025

Tranexamic acid inhibits group A streptococci-mediated fibrinolysis

Maresa Possehl, Praveen Vasudevan, Sonja Schenk, Claudia Maletzki, Robert David, Bernd Kreikemeyer, Sonja Oehmcke-Hecht

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maresa PossehlInstitute of Medical Microbiology, Virology and Hygiene, Rostock University Medical Center, Rostock, Germany.
Praveen VasudevanRudolf-Zenker-Institute for Experimental Surgery, Rostock University Medical Center, Rostock, Germany.
Sonja SchenkInstitute of Medical Microbiology, Virology and Hygiene, Rostock University Medical Center, Rostock, Germany.
Claudia MaletzkiDepartment of Medicine, Clinic III-Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Rostock, Germany.
Robert DavidDepartment of Cardiac Surgery, Rostock University Medical Center, Rostock, Germany.
Bernd KreikemeyerInstitute of Medical Microbiology, Virology and Hygiene, Rostock University Medical Center, Rostock, Germany.
Sonja Oehmcke-HechtInstitute of Medical Microbiology, Virology and Hygiene, Rostock University Medical Center, Rostock, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Group A Streptococcus (GAS) exploits the host fibrinolytic system by activating plasminogen via streptokinase, promoting clot degradation, tissue invasion, and immune evasion. Tranexamic acid (TXA), a clinically used antifibrinolytic agent, inhibits fibrinolysis, but its impact on GAS virulence and host immune responses remains incompletely understood. We investigated whether clinically relevant concentrations of TXA or ϵ-aminocaproic acid (AHA) inhibit GAS-induced fibrinolysis, affect bacterial survival in blood, and modulate host immune responses.

Indexed as

Antifibrinolytic AgentsFibrinolysisStreptococcal InfectionsStreptococcus pyogenesTranexamic AcidAnimalsDisease Models, AnimalFemaleHost-Pathogen InteractionsHumansMicePlasminogenAntifibrinolytic AgentsPlasminogenTranexamic Acidfibrinolysisgroup a streptococcusinnate immune cellspneumosepsistxa

Identifiers

PMID41322414
PMCPMC12660259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.